Acumen Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals

Charlottesville, va., april 16, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), will present the comprehensive clinical and biomarker results from its positive phase 1 intercept-ad study of sabirnetug (acu193) in early ad during an emerging science session at the american academy of neurology (aan) 2024 annual meeting in denver on april 16, 2024. the results build upon acumen's prior presentations at the ad/pd™ 2024 annual meeting and positive topline data first announced in july 2023 and will be presented together for the first time with expanded analysis.

Charlottesville, va. and basel, switzerland, april 04, 2024 (globe newswire) -- acumen pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), has signed a collaboration agreement with lonza, a global partner to the pharmaceutical, biotech and nutraceutical markets. the agreement covers the manufacture of sabirnetug (acu193), an antibody targeting toxic soluble aΒos for the treatment of ad, for clinical development and commercialization, if approved.

Charlottesville, va., march 26, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), today reported financial results for the full year ended december 31, 2023 and provided a business update.

Charlottesville, va., march 19, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, today announced that the company will report fourth quarter and year-end 2023 financial results on tuesday, march 26, 2024. the company will host a conference call and live audio webcast at 8:00 a.m. et to provide a business and financial update.

Charlottesville, va., march 12, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will participate in a fireside chat as part of the stifel 2024 cns days on tuesday, march 19, 2024, at 12:00 p.m. et.

Acumen Pharmaceuticals (ABOS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Acumen Pharmaceuticals (ABOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Ayr Wellness Inc. (AYRWF) have performed compared to their sector so far this year.

CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2023 financial results on Tuesday, March 26, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.

-   Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD

As investors, we are often looking to diversify our portfolios. Especially with the wild AI craze in the past year, many investors already hold positions in AI or other technology companies.

Aging stocks (or longevity stocks) are drawing attention from investors for obvious reasons. The Baby Boomer generation is now almost fully retired, and Gen X is right on its heels.

CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will present at the 42nd Annual J.P.

CHARLOTTESVILLE, Va. and INDIANAPOLIS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that it will present deeper insights and new exploratory findings from its Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AβO-directed antibody therapy for early AD, at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in Boston and online from October 24-27, 2023. INTERCEPT-AD was selected to be featured in a symposium on Friday, October 27, and data from exploratory analyses of the Phase 1 trial will also be shared in two in-person and two virtual poster presentations.